{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:16:11Z","timestamp":1793301371703,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.exer.2021.108482","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T16:29:10Z","timestamp":1612369750000},"page":"108482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["RNA therapeutics in ophthalmology - translation to clinical trials"],"prefix":"10.1016","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-4833","authenticated-orcid":false,"given":"Aanchal","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-345X","authenticated-orcid":false,"given":"Konstantinos N.","family":"Kafetzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4610-0803","authenticated-orcid":false,"given":"Aristides D.","family":"Tagalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-5187","authenticated-orcid":false,"given":"Cynthia","family":"Yu-Wai-Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.exer.2021.108482_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMe058142","article-title":"Angiogenic pathways in diabetic retinopathy","volume":"353","author":"Aiello","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.exer.2021.108482_bib3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ophtha.2009.10.002","article-title":"Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal\/grid photocoagulation for diabetic macular edema","volume":"117","author":"Aiello","year":"2010","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.exer.2021.108482_bib4","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI33494","article-title":"Nonviral delivery of synthetic siRNAs in vivo","volume":"117","author":"Akhtar","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.exer.2021.108482_bib5","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archophthalmol.2009.198","article-title":"Change in area of geographic atrophy in the age-related eye disease study: AREDS report number 26","volume":"127","author":"AREDS Research Group","year":"2009","journal-title":"Arch. Ophthalmol."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","article-title":"Pan-American collaborative retina study group. Primary intravitreal bevacizumab (avastin) for diabetic macular edema: results from the pan-American collaborative retina study group at 6-month follow-up","volume":"114","author":"Arevalo","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2021.108482_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.10.002","article-title":"The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy","volume":"62","author":"Athanasiou","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib8","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/bit.21285","article-title":"Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing","volume":"97","author":"Bartlett","year":"2007","journal-title":"Biotechnol. Bioeng."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/oli.2008.0164","article-title":"Chemical modification of siRNAs for in vivo use","volume":"18","author":"Behlke","year":"2008","journal-title":"Oligonucleotides"},{"issue":"14","key":"10.1016\/j.exer.2021.108482_bib10","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1167\/iovs.16-20303","article-title":"Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease","volume":"57","author":"Benitez-Del-Castillo","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.exer.2021.108482_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026466","article-title":"High-dose sirnas upregulate mouse Eri-1 at both transcription and posttranscription levels","volume":"6","author":"Bian","year":"2011","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.exer.2021.108482_bib12","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0161-6420(02)01069-2","article-title":"Efficacy and safety of mitomycin-C in primary trabeculectomy: five-year follow-up","volume":"109","author":"Bindlish","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2021.108482_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2180-1-34","article-title":"Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses","volume":"1","author":"Bitko","year":"2001","journal-title":"BMC Microbiol."},{"issue":"17","key":"10.1016\/j.exer.2021.108482_bib14","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1073\/pnas.171251798","article-title":"Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems","volume":"98","author":"Caplen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and Mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.12998\/wjcc.v3.i2.112","article-title":"Review and update on the molecular basis of Leber congenital amaurosis","volume":"3","author":"Chacon-Camacho","year":"2015","journal-title":"World J Clin Cases"},{"issue":"7","key":"10.1016\/j.exer.2021.108482_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.14304\/SURYA.JPR.V4N7.5","article-title":"RNA therapeutics: RNAi and antisense mechanisms and clinical applications","volume":"4","author":"Chery","year":"2016","journal-title":"Postdoc J."},{"issue":"3","key":"10.1016\/j.exer.2021.108482_bib18","first-page":"272","volume":"132","author":"Chew","year":"2014","journal-title":"Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report No. 36. JAMA Ophthalmol"},{"issue":"17","key":"10.1016\/j.exer.2021.108482_bib19","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1073\/pnas.0812317106","article-title":"Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth","volume":"106","author":"Cho","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"7387","key":"10.1016\/j.exer.2021.108482_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/bmj.326.7387.485","article-title":"Age related macular degeneration","volume":"326","author":"Chopdar","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41591-018-0295-0","article-title":"Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect","volume":"25","author":"Cideciyan","year":"2019","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/genes9040215","article-title":"Special issue introduction: inherited retinal disease: novel candidate genes, genotype-phenotype correlations, and inheritance models","volume":"9","author":"Cremers","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.exer.2021.108482_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.med.55.091902.104408","article-title":"Progress in antisense technology","volume":"55","author":"Crooke","year":"2004","journal-title":"Annu. Rev. Med."},{"issue":"8","key":"10.1016\/j.exer.2021.108482_bib24","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/ceo.12097","article-title":"Mitomycin C versus 5-fluorouracil as an adjunctive treatment for trabeculectomy: a meta-analysis of randomized clinical trials","volume":"41","author":"De Fendi","year":"2013","journal-title":"Clin. Exp. Ophthalmol."},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/hum.2008.928","article-title":"Delivery vehicles for small interfering RNA in vivo","volume":"19","author":"De Fougerolles","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.exer.2021.108482_bib26","first-page":"997","article-title":"Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes","volume":"14","author":"Dejneka","year":"2008","journal-title":"Mol. Vis."},{"issue":"3","key":"10.1016\/j.exer.2021.108482_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/507318","article-title":"Mutations in the CEP290 (NPHP6) gene are a frequent cause of leber congenital amaurosis","volume":"79","author":"Den Hollander","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.exer.2021.108482_bib28","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrd1345","article-title":"siRNAs: applications in functional genomics and potential as therapeutics","volume":"3","author":"Dorsett","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.exer.2021.108482_bib30","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.omtn.2018.07.010","article-title":"Splice-modulating oligonucleotide QR-110 restores CEP290 mRNA and function in human c.2991+1655A>G LCA10 models","volume":"12","author":"Dulla","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"9","key":"10.1016\/j.exer.2021.108482_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther."},{"issue":"5 Suppl. l","key":"10.1016\/j.exer.2021.108482_bib32","first-page":"766","article-title":"ETDRS report number 9. Early treatment diabetic retinopathy study research group","volume":"98","author":"Early photocoagulation for diabetic retinopathy","year":"1991","journal-title":"Ophthalmology"},{"issue":"6836","key":"10.1016\/j.exer.2021.108482_bib33","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.exer.2021.108482_bib34","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1093\/emboj\/20.23.6877","article-title":"Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate","volume":"20","author":"Elbashir","year":"2001","journal-title":"EMBO J."},{"issue":"5370","key":"10.1016\/j.exer.2021.108482_bib35","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1126\/science.280.5370.1753","article-title":"Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa","volume":"280","author":"Eudy","year":"1998","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.exer.2021.108482_bib36","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.ymthe.2018.09.004","article-title":"Development of targeted siRNA nanocomplexes to prevent fibrosis in experimental glaucoma filtration surgery","volume":"26","author":"Fernando","year":"2018","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.exer.2021.108482_bib37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2005.06.023","article-title":"RNAi: the nuts and bolts of the RISC machine","volume":"122","author":"Filipowicz","year":"2005","journal-title":"Cell"},{"issue":"6669","key":"10.1016\/j.exer.2021.108482_bib39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.exer.2021.108482_bib40","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","article-title":"Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1","volume":"16","author":"Forsythe","year":"1996","journal-title":"Mol. Cell Biol."},{"issue":"22","key":"10.1016\/j.exer.2021.108482_bib41","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1093\/nar\/25.22.4429","article-title":"The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA: RNA duplexes","volume":"25","author":"Freier","year":"1997","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/ng.2578","article-title":"Seven new loci associated with age-related macular degeneration","volume":"45","author":"Fritsche","year":"2013","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.exer.2010.07.014","article-title":"The pathogenic role of transforming growth factor-\u03b22 in glaucomatous damage to the optic nerve head","volume":"93","author":"Fuchshofer","year":"2011","journal-title":"Exp. Eye Res."},{"issue":"9","key":"10.1016\/j.exer.2021.108482_bib44","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0161-6420(03)00568-2","article-title":"Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema","volume":"110","author":"Funatsu","year":"2003","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.exer.2021.108482_bib45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ophtha.2004.11.045","article-title":"Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema","volume":"112","author":"Funatsu","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2021.108482_bib46","doi-asserted-by":"crossref","DOI":"10.4137\/OED.S4878","article-title":"Bevasiranib for the treatment of wet, age-related macular degeneration","volume":"2","author":"Garba","year":"2010","journal-title":"Ophthalmol. Eye Dis."},{"issue":"13","key":"10.1016\/j.exer.2021.108482_bib47","first-page":"564","article-title":"Phase 2 of bamosiran (SYL040012), a novel RNAi based compound for the treatment of increased intraocular pressure associated to glaucoma","volume":"55","author":"Gonzalez","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.exer.2021.108482_bib48","first-page":"1143","article-title":"Therapeutic targeting in the silent era: advances in non-viral siRNA delivery","volume":"6","author":"Guo","year":"2010","journal-title":"Mol. Biosyst."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib49","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bph.12330","article-title":"Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy","volume":"170","author":"Guzman-Aranguez","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-1-40","article-title":"Retinitis pigmentosa","volume":"1","author":"Hamel","year":"2006","journal-title":"Orphanet J. Rare Dis."},{"issue":"5441","key":"10.1016\/j.exer.2021.108482_bib51","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.286.5441.950","article-title":"A species of small antisense RNA in posttranscriptional gene silencing in plants","volume":"286","author":"Hamilton","year":"1999","journal-title":"Science"},{"issue":"6775","key":"10.1016\/j.exer.2021.108482_bib52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/35005107","article-title":"An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells","volume":"404","author":"Hammond","year":"2000","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.exer.2021.108482_bib53","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bcp.2005.11.015","article-title":"Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum","volume":"71","author":"Haupenthal","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.exer.2021.108482_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00128413-199811380-00019","article-title":"Fomivirsen focuses on the future in CMV retinitis","volume":"1138","author":"Henahan","year":"1998","journal-title":"Inpharma Wkly."},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib55","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm1709","article-title":"Oxidative damage-induced inflammation initiates age-related macular degeneration","volume":"14","author":"Hollyfield","year":"2008","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.exer.2021.108482_bib56","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","article-title":"Van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s004170000241","article-title":"Transforming growth factor-\u03b22 levels in aqueous humor of glaucomatous eyes","volume":"239","author":"Inatani","year":"2001","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"issue":"7","key":"10.1016\/j.exer.2021.108482_bib58","first-page":"4305","article-title":"Development of IONIS-FB-LRx to treat geographic atrophy associated with AMD","volume":"61","author":"Jaffe","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"7228","key":"10.1016\/j.exer.2021.108482_bib59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature07755","article-title":"A three-dimensional view of the molecular machinery of RNA interference","volume":"457","author":"Jinek","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.exer.2021.108482_bib60","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ophtha.2010.08.044","article-title":"Prevalence of age-related macular degeneration in old persons: age, gene\/environment susceptibility Reykjavik study","volume":"118","author":"Jonasson","year":"2011","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.exer.2021.108482_bib61","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1093\/nar\/gkn342","article-title":"Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides","volume":"36","author":"Juliano","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2010.02.006","article-title":"Sirna-027 study investigators. RNAi-based treatment for neovascular age-related macular degeneration by sirna-027","volume":"150","author":"Kaiser","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108482_bib63","first-page":"1","article-title":"Antisense oligonucleotides, a novel developing targeting therapy","author":"Karaki","year":"2019","journal-title":"IntechOpen - Antisense Therapy"},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib64","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1038\/mtna.2011.4","article-title":"SiRNA-optimized modifications for enhanced in vivo activity","volume":"1","author":"Kenski","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"6","key":"10.1016\/j.exer.2021.108482_bib65","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0161-6420(92)31871-8","article-title":"Prevalence of age-related maculopathy: the beaver dam eye study","volume":"99","author":"Klein","year":"1992","journal-title":"Ophthalmology"},{"issue":"7187","key":"10.1016\/j.exer.2021.108482_bib66","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature06765","article-title":"Sequence- and target-independent angiogenesis suppression by siRNA via TLR3","volume":"452","author":"Kleinman","year":"2008","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.exer.2021.108482_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","article-title":"Viral vectors for gene therapy: translational and clinical outlook","volume":"17","author":"Kotterman","year":"2015","journal-title":"Annu. Rev. Biomed. Eng."},{"issue":"3","key":"10.1016\/j.exer.2021.108482_bib69","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000027415","article-title":"Blindness incidence in Germany: a population-based study from Wurttemberg-Hohenzollern","volume":"213","author":"Krumpaszky","year":"1999","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.exer.2021.108482_bib70","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0896-1549(02)00034-2","article-title":"Novel approaches for retinal drug delivery","volume":"15","author":"Kurz","year":"2002","journal-title":"Ophthalmol Clin North Am."},{"issue":"3","key":"10.1016\/j.exer.2021.108482_bib71","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0039-6257(03)00038-9","article-title":"Antifibrotics and wound healing in glaucoma surgery","volume":"48","author":"Lama","year":"2003","journal-title":"Surv. Ophthalmol."},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international Dry Eye WorkShop","volume":"5","author":"Lemp","year":"2007","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.exer.2021.108482_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.exer.2014.02.018","article-title":"The effect of the common c.2299delG mutation in USH2A on RNA splicing","volume":"122","author":"Lenassi","year":"2014","journal-title":"Exp. Eye Res."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib75","first-page":"208","article-title":"Smart nanoparticles assembled by endogenous molecules for siRNA delivery and cancer therapy via CD44 and EGFR dual-targeting. Nanomedicine Nanotechnology","volume":"15","author":"Liang","year":"2019","journal-title":"Biol. Med."},{"key":"10.1016\/j.exer.2021.108482_bib76","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/B978-0-12-407676-1.00002-0","article-title":"Biological activity and biotechnological aspects of locked nucleic acids","volume":"82","author":"Lundin","year":"2013","journal-title":"Adv. Genet."},{"issue":"6","key":"10.1016\/j.exer.2021.108482_bib77","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ymben.2006.07.005","article-title":"Impact of RNA interference on gene networks","volume":"8","author":"Malphettes","year":"2006","journal-title":"Metab. Eng."},{"issue":"5","key":"10.1016\/j.exer.2021.108482_bib78","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0092-8674(02)00908-X","article-title":"Single-stranded antisense siRNAs guide target RNA cleavage in RNAi","volume":"110","author":"Martinez","year":"2002","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.exer.2021.108482_bib79","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbadis.2014.11.020","article-title":"Usher syndrome: hearing loss, retinal degeneration and associated abnormalities","volume":"1852","author":"Mathur","year":"2015","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"7006","key":"10.1016\/j.exer.2021.108482_bib80","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature02873","article-title":"Mechanisms of gene silencing by double-stranded RNA","volume":"431","author":"Meister","year":"2004","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.exer.2021.108482_bib81","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3341\/kjo.2006.20.3.162","article-title":"Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes","volume":"20","author":"Min","year":"2006","journal-title":"Kor. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib82","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/mt.2013.217","article-title":"Phase I clinical trial of SYL040012, a small interfering RNA targeting \u03b2-adrenergic receptor 2, for lowering intraocular pressure","volume":"22","author":"Moreno-Monta\u00f1\u00e9s","year":"2014","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.exer.2021.108482_bib83","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0161-6420(98)96025-0","article-title":"The 14-year incidence of visual loss in a diabetic population","volume":"105","author":"Moss","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2021.108482_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.8601.1","article-title":"Thirty-five years of research into ribozymes and nucleic acid catalysis: where do we stand today?","volume":"5","author":"M\u00fcller","year":"2016","journal-title":"F1000Research"},{"issue":"11","key":"10.1016\/j.exer.2021.108482_bib85","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1167\/iovs.15-16400","article-title":"Allele-specific inhibition of rhodopsin with an antisense oligonucleotide slows photoreceptor cell degeneration","volume":"56","author":"Murray","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.exer.2021.108482_bib86","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","article-title":"READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for edema of the macula in diabetes (READ-2) study","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.exer.2021.108482_bib87","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","article-title":"Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study","volume":"117","author":"Nguyen","year":"2010","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.exer.2021.108482_bib88","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/eye.2012.106","article-title":"Chi- Burris K, Yan E, Paggiarino DA, Rosenblatt I, Khan A. Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients","volume":"26","author":"Nguyen","year":"2012","journal-title":"Eye"},{"issue":"12","key":"10.1016\/j.exer.2021.108482_bib89","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1167\/iovs.12-9961","article-title":"Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study)","volume":"53","author":"Nguyen","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"9","key":"10.1016\/j.exer.2021.108482_bib90","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.ophtha.2012.03.043","article-title":"Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study)","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.exer.2021.108482_bib92","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0021-5155(01)00523-8","article-title":"Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes","volume":"46","author":"Ochiai","year":"2002","journal-title":"Jpn. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.exer.2021.108482_bib93","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/IJG.0b013e318285fd7d","article-title":"Using the early postoperative intraocular pressure to predict pressure control after a trabeculectomy","volume":"23","author":"Okimoto","year":"2014","journal-title":"J. Glaucoma"},{"issue":"11","key":"10.1016\/j.exer.2021.108482_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0188899","article-title":"First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-\u03b22), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery","volume":"12","author":"Pfeiffer","year":"2017","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib95","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1542-0124(12)70085-X","article-title":"Management and therapy of dry eye disease: report of the management and therapy subcommittee of the international Dry Eye WorkShop","volume":"5","author":"Pflugfelder","year":"2007","journal-title":"Ocul. Surf."},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib96","first-page":"1","article-title":"A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges","volume":"2015","author":"Phadatare","year":"2015","journal-title":"Adv. Pharm."},{"issue":"27","key":"10.1016\/j.exer.2021.108482_bib97","doi-asserted-by":"crossref","first-page":"17897","DOI":"10.1074\/jbc.R900012200","article-title":"The RNA-induced silencing complex: a versatile gene-silencing machine","volume":"284","author":"Pratt","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2021.108482_bib98","author":"ProQR"},{"issue":"5","key":"10.1016\/j.exer.2021.108482_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/wrna.1594","article-title":"The powerful world of antisense oligonucleotides: from bench to bedside","volume":"11","author":"Quemener","year":"2020","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"3","key":"10.1016\/j.exer.2021.108482_bib100","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib101","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.genet.33.1.89","article-title":"Molecular genetics of human retinal disease","volume":"33","author":"Rattner","year":"1999","journal-title":"Annu. Rev. Genet."},{"issue":"11","key":"10.1016\/j.exer.2021.108482_bib102","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bull. World Health Organ."},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib103","first-page":"717","article-title":"Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice","volume":"149","author":"Rifai","year":"1996","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/practneurol-2017-001764","article-title":"Antisense oligonucleotides and other genetic therapies made simple","volume":"18","author":"Rossor","year":"2018","journal-title":"Practical Neurol."},{"key":"10.1016\/j.exer.2021.108482_bib106","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2147\/OPTH.S29909","article-title":"Comparative study between trabeculectomy with photodynamic therapy (BCECF-AM) and trabeculectomy with antimetabolite (MMC) in the treatment of primary open angle glaucoma","volume":"6","author":"Saeed","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108482_bib107","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/OED.S16067","article-title":"Safety and efficacy of cyclosporine in the treatment of chronic dry eye","volume":"6","author":"Schultz","year":"2014","journal-title":"Ophthalmol. Eye Dis."},{"issue":"6","key":"10.1016\/j.exer.2021.108482_bib108","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.ophtha.2017.12.013","article-title":"Leber congenital amaurosis associated with mutations in CEP290, clinical phenotype, and natural history in preparation for trials of novel therapies","volume":"125","author":"Sheck","year":"2018","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.exer.2021.108482_bib109","first-page":"469","article-title":"Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis","volume":"39","author":"Shibuya","year":"2006","journal-title":"J. Biochem. Mol. Biol."},{"issue":"6","key":"10.1016\/j.exer.2021.108482_bib110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/IAE.0b013e3181ad2341","article-title":"Combination therapy using the small interfering RNA bevasiranib","volume":"29","author":"Singerman","year":"2009","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib111","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib112","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib113","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/oli.1.1997.7.63","article-title":"Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.exer.2021.108482_bib114","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.actbio.2017.01.048","article-title":"Peptide and nucleic acid-directed self-assembly of cationic nanovehicles through giant unilamellar vesicle modification: targetable nanocomplexes for in vivo nucleic acid delivery","volume":"51","author":"Tagalakis","year":"2017","journal-title":"Acta Biomater."},{"issue":"7","key":"10.1016\/j.exer.2021.108482_bib115","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s11095-017-2134-2","article-title":"The race of 10 synthetic RNAi-based drugs to the pharmaceutical market","volume":"34","author":"Titze-de-Almeida","year":"2017","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"5","key":"10.1016\/j.exer.2021.108482_bib116","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/jop.2010.0100","article-title":"Influence of race and age on aqueous humor levels of transforming growth factor-beta 2 in glaucomatous and nonglaucomatous eyes","volume":"27","author":"Trivedi","year":"2011","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2021.108482_bib117","unstructured":"Usher syndrome Database. Available from:: https:\/\/grenada.lumc.nl\/LOVD2\/Usher_montpellier\/USHbases.html."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib118","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF00046448","article-title":"Evidence for sense RNA-mediated protection to PVYN in tobacco plants transformed with the viral coat protein cistron","volume":"20","author":"van der Vlugt","year":"1992","journal-title":"Plant Mol. Biol."},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib119","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.exer.2021.108482_bib120","first-page":"420","article-title":"Distribution and properties of \u03b2-adrenergic receptors in human iris-ciliary body","volume":"28","author":"Wax","year":"1987","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.exer.2021.108482_bib121","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1086\/302855","article-title":"Genomic structure and identification of novel mutations in Usherin, the gene responsible for usher syndrome type IIa","volume":"66","author":"Weston","year":"2000","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.exer.2021.108482_bib122","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Heal"},{"issue":"7","key":"10.1016\/j.exer.2021.108482_bib123","first-page":"5714","article-title":"Preclinical profile of ISTH0036, a potent and selective antisense oligonucleotide targeting transforming growth factor beta 2 (TGF-\u03b22) for the treatment of ophthalmic diseases","volume":"56","author":"Wosikowski","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.exer.2021.108482_bib124","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.7150\/thno.43360","article-title":"Advances in CRISPR\/Cas-based gene therapy in human genetic diseases","volume":"10","author":"Wu","year":"2020","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.exer.2021.108482_bib125","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2020.1804853","article-title":"Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases","volume":"29","author":"Xue","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.exer.2021.108482_bib126","doi-asserted-by":"crossref","first-page":"21881","DOI":"10.1038\/srep21881","article-title":"Receptor-targeted liposome-peptide-siRNA nanoparticles represent an efficient delivery system for MRTF silencing in conjunctival fibrosis","volume":"6","author":"Yu-Wai-Man","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.exer.2021.108482_bib127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0092-8674(00)80620-0","article-title":"RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals","volume":"101","author":"Zamore","year":"2000","journal-title":"Cell"},{"issue":"6865","key":"10.1016\/j.exer.2021.108482_bib128","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483521000476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483521000476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:09:35Z","timestamp":1757999375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483521000476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":127,"alternative-id":["S0014483521000476"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2021.108482","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA therapeutics in ophthalmology - translation to clinical trials","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2021.108482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108482"}}